|
Welcome
Vaxin Inc. is an emerging vaccine company using non-invasive means to elicit immune responses. Our lead programs are vaccines to prevent disease caused by influenza (phase I), anthrax, Avian Influenza, Tetanus, and Alzheimer.
Our Technology
The Company’s proprietary technology consists of non-replicating adenovirus and bacterial vectors that can deliver antigens non-invasively (to the nasal passages or to the skin) to elicit a protective immune response. The nasal mucosa and the skin contain cells that participate in the body’s protection mechanism against disease causing pathogens. Vaxin’s technology harnesses this pre-existing feature of our immune system.
CLICK FOR MORE INFORMATION
|
Press Releases
DAVID BRAKE PH.D. TO JOIN VAXIN'S BOARD OF DIRECTORS- February 6, 2013
Press Release VAXIN ANNOUNCES THE APPOINTMENT OF M. SCOT ROBERTS TO
CHIEF SCIENTIFIC OFFICER- December 3, 2012
Press ReleaseVAXIN APPOINTS BRIGADIER GENERAL (RET.) KLAUS SCHAFER TO BOARD OF DIRECTORS- JULY 10, 2012
Press ReleaseVAXIN RECEIVES PHASE I SBIR GRANT TO EVALUATE PROMISING NEW ANTHRAX VACCINE- June 18, 2012
Press Release
VAXIN & AUBURN UNIVERSITY RECEIVE MILLION DOLLAR GRANT FROM FOUND ANIMALS FOUNDATION TO DEVELOP A VACCINE TO STERILIZE DOGS AND CATS- December 5, 2011
Press Release
VAXIN ANNOUNCES APPOINTMENT OF DR. DAVID DRUTZ CHAIRMAN- October 13, 2011
Press Release
BIRMINGHAM'S VAXIN LANDS $14.7 MILLION FEDERAL GRANT FOR WORK ON ANTHRAX VACCINE - September 25, 2011
Birmingham News
VAXIN AWARDED BARDA CONTRACT VALUED AT UP TO $21.7M TO DEVELOP NEXT GENERATION ANTHRAX VACCINE - September 16, 2011
Press Release
VAXIN ANNOUNCES ANTHRAX VACCINE COLLABORATION AGREEMENT WITH STABILITECH - September 8, 2010
Press Release
|
